TICKERNOMICS Sign up
Last Update: 2024-03-28 02:13:14
Astria Therapeutics Inc. ( ATXS ) https://www.astriatx.com
13.53USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
ATXS
10.63%
SPY
32.74%
-21.70%
ATXS
SPY
92.93%
-71.53%
ATXS
SPY
224.41%
ATXS
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
555.20
486.99
1.81
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-10.80
1110.40
2.28
-25.09
0.00
-6.92
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.5151
-70.44
-34.21
0.87
Other Earnings and Cash Flow Stats:
Astria Therapeutics Inc. ( ATXS ) Net Income TTM ($MM) is -50.02
Astria Therapeutics Inc. ( ATXS ) Operating Income TTM ($MM) is -60.41
Astria Therapeutics Inc. ( ATXS ) Owners' Earnings Annual ($MM) is -42.74
Astria Therapeutics Inc. ( ATXS ) Current Price to Owners' Earnings ratio is -8.69
Astria Therapeutics Inc. ( ATXS ) EBITDA TTM ($MM) is -62.28
Astria Therapeutics Inc. ( ATXS ) EBITDA Margin is 0.00%
Capital Allocation:
Astria Therapeutics Inc. ( ATXS ) has paid 0.00 dividends per share and bought back -26.414179 million shares in the past 12 months
Astria Therapeutics Inc. ( ATXS ) has reduced its debt by 0.145 million USD in the last 12 months
Capital Structure:
Astria Therapeutics Inc. ( ATXS ) Interest-bearing Debt ($MM) as of last quarter is 0
Astria Therapeutics Inc. ( ATXS ) Annual Working Capital Investments ($MM) are 0
Astria Therapeutics Inc. ( ATXS ) Book Value ($MM) as of last quarter is 243
Astria Therapeutics Inc. ( ATXS ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Astria Therapeutics Inc. ( ATXS ) has 175 million in cash on hand as of last quarter
Astria Therapeutics Inc. ( ATXS ) has 11 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Astria Therapeutics Inc. ( ATXS ) has 41 common shares outstanding as of last quarter
Astria Therapeutics Inc. ( ATXS ) has 95 million USD of preferred stock value
Academic Scores:
Astria Therapeutics Inc. ( ATXS ) Altman Z-Score is 25.88 as of last quarter
Astria Therapeutics Inc. ( ATXS ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Astria Therapeutics Inc. ( ATXS ) largest shareholder is Tri Locum Partners LP owning 598128 shares at 8.09 ($MM) value
Perceptive Advisors Llc(an insider) Bought 2481350 shares of Astria Therapeutics Inc. ( ATXS ) for the amount of $29999521.50 on 2024-02-01
0.74% of Astria Therapeutics Inc. ( ATXS ) is held by insiders, and 66.57% is held by institutions
Astria Therapeutics Inc. ( ATXS ) went public on 2015-06-25
Other Astria Therapeutics Inc. ( ATXS ) financial metrics:
FCF:-48.52
Unlevered Free Cash Flow:-59.00
EPS:-1.73
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-29.17
Beta:0.87
Buffet's Owners Earnings:-42.74
Price to Owner's Earnings:-8.69
About Astria Therapeutics Inc. ( ATXS ) :
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.